Monte Rosa Therapeutics (GLUE) Equity Average (2023 - 2025)
Historic Equity Average for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $257.0 million.
- Monte Rosa Therapeutics' Equity Average rose 1948.0% to $257.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.0 million, marking a year-over-year increase of 1948.0%. This contributed to the annual value of $201.1 million for FY2024, which is N/A changed from last year.
- Per Monte Rosa Therapeutics' latest filing, its Equity Average stood at $257.0 million for Q3 2025, which was up 1948.0% from $271.6 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Equity Average ranged from a high of $271.6 million in Q2 2025 and a low of $165.9 million during Q1 2024
- Its 3-year average for Equity Average is $217.1 million, with a median of $214.6 million in 2024.
- As far as peak fluctuations go, Monte Rosa Therapeutics' Equity Average tumbled by 1753.25% in 2024, and later soared by 5013.34% in 2025.
- Monte Rosa Therapeutics' Equity Average (Quarter) stood at $181.9 million in 2023, then rose by 17.76% to $214.2 million in 2024, then rose by 19.96% to $257.0 million in 2025.
- Its Equity Average was $257.0 million in Q3 2025, compared to $271.6 million in Q2 2025 and $249.0 million in Q1 2025.